BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35337747)

  • 1. Targeting prostate lesions on multiparametric MRI with HDR brachytherapy: Optimal planning margins determined using whole-mount digital histology.
    Smith CW; Marcus T; Hoover D; Surry K; D'Souza D; Cool D; Kassam Z; Bastian-Jordan M; Gómez JA; Moussa M; Chin JL; Pautler S; Bauman GS; Ward AD
    Brachytherapy; 2022; 21(4):435-441. PubMed ID: 35337747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multiobserver study investigating the effectiveness of prostatic multiparametric magnetic resonance imaging to dose escalate corresponding histologic lesions using high-dose-rate brachytherapy.
    Smith CW; Hoover D; Surry K; D'Souza D; Cool DW; Kassam Z; Bastian-Jordan M; Gomez JA; Moussa M; Chin J; Pautler S; Bauman GS; Ward AD
    Brachytherapy; 2021; 20(3):601-610. PubMed ID: 33648893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetric evaluation of MRI-to-ultrasound automated image registration algorithms for prostate brachytherapy.
    Shaaer A; Paudel M; Davidson M; Semple M; Nicolae A; Mendez LC; Chung H; Loblaw A; Tseng CL; Morton G; Ravi A
    Brachytherapy; 2020; 19(5):599-606. PubMed ID: 32712028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of catheter displacement and anatomical variations on the dose distribution in MRI-guided focal HDR brachytherapy for prostate cancer.
    Maenhout M; van der Voort van Zyp JRN; Borot de Battisti M; Peters M; van Vulpen M; van den Bosch M; Moerland MA
    Brachytherapy; 2018; 17(1):68-77. PubMed ID: 28579419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viability of focal dose escalation to prostate cancer intraprostatic lesions using HDR prostate brachytherapy.
    Poder J; Radvan S; Howie A; Kasraei F; Parker A; Bucci J; Haworth A
    Brachytherapy; 2023; 22(6):800-807. PubMed ID: 37748989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose to the dominant intraprostatic lesion using HDR vs. LDR monotherapy: A Phase II randomized trial.
    Tissaverasinghe S; Crook J; Bachand F; Batchelar D; Hilts M; Araujo C; Anderson D; Bainbridge T; Farnquist B
    Brachytherapy; 2019; 18(3):299-305. PubMed ID: 30795889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiomics based targeted radiotherapy planning (Rad-TRaP): a computational framework for prostate cancer treatment planning with MRI.
    Shiradkar R; Podder TK; Algohary A; Viswanath S; Ellis RJ; Madabhushi A
    Radiat Oncol; 2016 Nov; 11(1):148. PubMed ID: 27829431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosimetric feasibility of ablative dose escalated focal monotherapy with MRI-guided high-dose-rate (HDR) brachytherapy for prostate cancer.
    Hosni A; Carlone M; Rink A; Ménard C; Chung P; Berlin A
    Radiother Oncol; 2017 Jan; 122(1):103-108. PubMed ID: 27916416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance imaging-defined treatment margins in iodine-125 prostate brachytherapy.
    Crook J; Patil N; Ma C; McLean M; Borg J
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1079-84. PubMed ID: 19879700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosimetry Modeling for Focal Low-Dose-Rate Prostate Brachytherapy.
    Al-Qaisieh B; Mason J; Bownes P; Henry A; Dickinson L; Ahmed HU; Emberton M; Langley S
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):787-93. PubMed ID: 25936808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of multiparametric MRI-based and transrectal ultrasound-based preplans with intraoperative ultrasound-based planning for low dose rate interstitial prostate seed implantation.
    Fredman ET; Traughber BJ; Gross A; Podder T; Colussi V; Vinkler R; Machtay M; Ellis RJ
    J Appl Clin Med Phys; 2019 Jun; 20(6):31-38. PubMed ID: 31004396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of HDR brachytherapy-replicating prostate radiotherapy planning for tomotherapy, cyberknife and VMAT.
    de Chavez R; Grogan G; Hug B; Howe K; Grigg A; Waterhouse D; Lane J; Glyde A; Brown E; Bydder S; Pryor D; Hargrave C; Charles PH; Hellyer J; Ebert MA
    Med Dosim; 2022 Spring; 47(1):61-69. PubMed ID: 34551879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosimetric impact of contouring and needle reconstruction uncertainties in US-, CT- and MRI-based high-dose-rate prostate brachytherapy treatment planning.
    Rylander S; Buus S; Pedersen EM; Bentzen L; Tanderup K
    Radiother Oncol; 2017 Apr; 123(1):125-132. PubMed ID: 28284493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focal dose escalation for prostate cancer using
    Zamboglou C; Thomann B; Koubar K; Bronsert P; Krauss T; Rischke HC; Sachpazidis I; Drendel V; Salman N; Reichel K; Jilg CA; Werner M; Meyer PT; Bock M; Baltas D; Grosu AL
    Radiat Oncol; 2018 May; 13(1):81. PubMed ID: 29716617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of an MRI-to-ultrasound deformable image registration algorithm for prostate brachytherapy.
    Shaaer A; Davidson M; Semple M; Nicolae A; Mendez LC; Chung H; Loblaw A; Tseng CL; Morton G; Ravi A
    Brachytherapy; 2019; 18(1):95-102. PubMed ID: 30287271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy.
    Hegde JV; Demanes DJ; Veruttipong D; Raince J; Park SJ; Raman SS; Nickols NG; King CR; Kishan AU; Steinberg ML; Kamrava M
    Brachytherapy; 2017; 16(6):1106-1112. PubMed ID: 28807747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pattern of relapse and dose received by the recurrent intraprostatic nodule in low- to intermediate-risk prostate cancer treated with single fraction 19 Gy high-dose-rate brachytherapy.
    Mendez LC; Ravi A; Chung H; Tseng CL; Wronski M; Paudel M; McGuffin M; Cheung P; Loblaw A; Morton G
    Brachytherapy; 2018; 17(2):291-297. PubMed ID: 29137956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate specific membrane antigen positron emission tomography for lesion-directed high-dose-rate brachytherapy dose escalation.
    Smith CW; Alfano R; Hoover D; Surry K; D'Souza D; Thiessen J; Rachinsky I; Butler J; Gomez JA; Gaed M; Moussa M; Chin J; Pautler S; Bauman GS; Ward AD
    Phys Imaging Radiat Oncol; 2021 Jul; 19():102-107. PubMed ID: 34589619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiparametric MRI-guided dose boost to dominant intraprostatic lesions in CT-based High-dose-rate prostate brachytherapy.
    Wang T; Press RH; Giles M; Jani AB; Rossi P; Lei Y; Curran WJ; Patel P; Liu T; Yang X
    Br J Radiol; 2019 May; 92(1097):20190089. PubMed ID: 30912959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetric and workflow impact of synthetic-MRI use in prostate high-dose-rate brachytherapy.
    Podgorsak AR; Venkatesulu BP; Abuhamad M; Harkenrider MM; Solanki AA; Roeske JC; Kang H
    Brachytherapy; 2023; 22(5):686-696. PubMed ID: 37316376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.